1.
Retin Cases Brief Rep
; 13(3): 287-289, 2019.
Article
in English
| MEDLINE
| ID: mdl-28301410
ABSTRACT
PURPOSE: To describe the patient's allergic response to anti-vascular endothelial growth factor drugs after receiving intravitreal bevacizumab for choroidal neovascularization. METHODS: Clinical case report. RESULTS: Formal allergy evaluation revealed hypersensitivity to bevacizumab and ranibizumab, but not to pegaptanib or aflibercept. CONCLUSION: Bevacizumab and ranibizumab are derivatives of murine monoclonal antibodies, whereas pegaptanib is an aptamer and aflibercept is a fusion protein of human origin. These chemical origins may allow patients to receive pegaptanib or aflibercept despite having allergy to bevacizumab or ranibizumab.